This week we were joined by Dr. Jenny Seligmann. Dr. Seligmann is a Professor of Gastrointestinal and Translational Oncology and Honorary Consultant in Medical Oncology at the University of Leeds. Dr. Seligmann is one of the authors of the seminal FOxTROT trial, which investigated the use of neoadjuvant chemotherapy in advanced colon cancers. Dr. Seligmann is the lead investigator on the FOxTROT platform, the ARIEL trial, and continues to be on the leading edge of trials for colorectal cancer. In this episode, we explored neoadjuvant chemotherapy for colon cancer specifically. There's lots to take away from this conversation, but one of the things that stood out for us was some of the differences in the structure of the multidisciplinary tumor boards in Dr. Seligmann’s centre versus many centres in Canada. Perhaps in the future, all colorectal cancers will get discussed at tumor boards! What do you think? We’d love to hear your thoughts – email us at [email protected]:Dr Jenny Seligmann is Professor of Gastrointestinal and Translational Oncology and Honorary Consultant in Medical Oncology at the University of Leeds, UK. She is the Chief Investigator of the FOxTROT Platform and the ARIEL trial, and has a programme of translational research. She is a member of the ESMO Lower Gastrointestinal Faculty and the UK NCRI Colorectal Cancer Executive Group.x/twitter: @jenseligmannLinks:Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. https://ascopubs.org/doi/10.1200/JCO.22.00046Professor Dion Morton: https://www.birmingham.ac.uk/staff/profiles/applied-health/morton-dionProfessor Phil Quirke: https://medicinehealth.leeds.ac.uk/medicine/staff/700/professor-philip-quirkeARIEL trial: https://fundingawards.nihr.ac.uk/award/NIHR129268FOCUS4 trial: http://www.focus4trial.org/FOxTROT platform website: https://ctru.leeds.ac.uk/foxtrot/COLOSOS trial: https://mycs-cdn.myconferencesuite.com/other/Project/3222/91/c0/PRELIM%20PROGRAM_COLOSOS%20CANADA_DL.pdf

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related